Format

Send to

Choose Destination
Cancer Treat Res. 2016;167:181-208. doi: 10.1007/978-3-319-22539-5_7.

Adjuvant Therapy of Melanoma.

Author information

1
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA. davard@upmc.edu.
2
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA. kirkwoodjm@upmc.edu.

Abstract

The incidence of melanoma is rapidly increasing, especially in younger female and older male patients. Recent fundamental advances in our knowledge of melanoma tumorigenesis have established roles for inhibitors of the MAPK pathway and regulatory immune checkpoints CTLA-4 and PD-1/PD-L1. However, the majority of patients continue to present with non-metastatic disease-typically managed with surgical resection and adjuvant therapy. High-dose IFN-α2b (HDI) is the main adjuvant therapeutic mainstay in high-risk disease following definitive resection. In this chapter, we review the evidence supporting the use of adjuvant HDI in high-risk melanoma. We also discuss some of the other treatment modalities that have been evaluated including vaccines, chemotherapy, and radiotherapy.

KEYWORDS:

Adjuvant; CTLA-4; Chemotherapy; HDI; High-dose IFN-α2b; Ipilimumab; Melanoma; Nivolumab; PD-1; PD-L1; Pegylated IFN; Pembrolizumab; Radiotherapy; Vaccines

PMID:
26601863
DOI:
10.1007/978-3-319-22539-5_7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center